Alzheimer’s disease (AD) is currently recognized as an untreatable, progressive, degenerative and terminal disease that is global – afflicting over 36 million people worldwide, with the number growing in an unabated and frightening manner. The goal of the series Advances in Alzheimer’s Research , with Volumes 1 and 2, is to provide an integrated approach to AD from basic and clinical research and to highlight the valuable information in order to unravel the origin, pathogenesis and prevention of AD. The aim of this book is to both capture and discuss improvements toward the diagnosis and potential treatment of AD by both established and novel strategies. This book series, including the Volume 2, provides an important mechanism to bring under the same roof a variety of scientific interests and expertise to specifically focus on AD and related dementias. The fullest attempt has been made to disseminate the most current knowledge on recent advances in potential therapy of AD.

Recent Advances in Alzheimer Disease Research is a book series focusing on contemporary research on Alzheimer’s disease epidemiology, pathophysiology, diagnosis and therapy. The series features reviews by experts in neuroscience and aims to provide current information in the field to both researchers and clinicians. Down syndrome is a chromosomal disorder affecting more than 5.8 million individuals worldwide. Down syndrome can be viewed as a complex multi-system disorder as it manifests into significant physical, psychological, and cognitive abnormalities in affected persons. With aging, most adults with Down syndrome develop the clinical and neuropathological hallmarks of Alzheimer's disease. Unfortunately, no extant treatments have proven beneficial for cognitive dysfunction for either Down syndrome or Alzheimer’s disease. An incomplete understanding of the common pathogenic mechanisms that link these two disorders has limited researchers’ progress to this end. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a novel attempt to fill this void, by summarizing the work of world-renowned scientists in the field of Alzheimer’s disease and Down syndrome, and thus providing an unprecedented opportunity to attract attention to Down syndrome as a tool for understanding the common molecular mechanisms that underlie Alzheimer’s disease and to develop new therapies for similar neurodegenerative disorders of the brain. The book covers the fundamental pathophysiology and molecular mechanisms behind the incidence of Alzheimer’s disease in Down syndrome affected individuals as well other key topics such as diagnosis and management, in vivo brain imaging studies, and progressive neurodegeneration of the monoaminergic system. The book concludes with a review of recent clinical trials of drugs designed to mitigate cognitive dysfunction in aging adults with Down syndrome and establishes a scientific warrant for the increased testing of candidate pharmacotherapies. Common Pathogenic Mechanisms between Down syndrome and Alzheimer's Disease: Steps toward Therapy is a useful reference clinicians involved in treating Down syndrome patients as well as for neuroscience researchers seeking to understand the influence of a specific case of aneuploidy on Alzheimer’s disease incidence and its progression at the molecular level.

A New Era in Alzheimer's Research: Pathogenesis, Prevention, and Treatment is focused on the research and perspectives in Alzheimer's disease (AD), offering an update on the challenging aspects of neurodegenerative disorders. Each chapter of this book contains unique and valuable scientific information on the latest progress of research in neurodevelopmental diseases. Even after years of research, Alzheimer's disease is still far from being cured; this book addresses the most current issues within the many dimensions relevant to the pathogenesis, diagnosis, and prevention under one cover, making it useful for researchers, students, and clinicians, as well as those in pharmaceuticals. - Contains basic knowledge about Alzheimer's disease and its causes and related pathology for a better understating of AD - Provides the multidisciplinary research on Alzheimer's disease in one source - Uniquely describes the details of the pathological, diagnostic, and preventive information for the potential development of novel anti-AD drugs - Includes hot topics, such as cerebrovascular pathology and lifestyle medicine, for the prevention of AD

Advances in Dementia Research and Treatment / 2012 Edition is a ScholarlyEditions™ eBook that delivers timely, authoritative, and comprehensive information about Dementia. The editors have built Advances in Dementia Research and Treatment / 2012 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Dementia in this eBook to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Advances in Dementia Research and Treatment / 2012 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

This is a book about living with Alzheimer’s, not dying with it. It is a book about hope, faith, and humor—a prescription far more powerful than the conventional medication available today to fight this disease. Alzheimer’s is the sixth leading cause of death in the US—and the only one of these diseases on the rise. More than 5 million Americans have been diagnosed with Alzheimer’s or a related dementia; about 35 million people worldwide. Greg O’Brien, an award-winning investigative reporter, has been diagnosed with early-onset Alzheimer's and is one of those faceless numbers. Acting on long-term memory and skill coupled with well-developed journalistic grit, O’Brien decided to tackle the disease and his imminent decline by writing frankly about the journey. O’Brien is a master storyteller. His story is naked, wrenching, and soul searching for a generation and their loved ones about to cross the threshold of this death in slow motion. On Pluto: Inside the Mind of Alzheimer’s is a trail-blazing roadmap for a generation—both a “how to” for fighting a disease, and a “how not” to give up!

Neurodegenerative Diseases—Advances in Research and Treatment: 2013 Edition is a ScholarlyEditions™ book that delivers timely, authoritative, and comprehensive information about Tauopathies. The editors have built Neurodegenerative Diseases—Advances in Research and Treatment: 2013 Edition on the vast information databases of ScholarlyNews.™ You can expect the information about Tauopathies in this book to be deeper than what you can access anywhere else, as well as consistently reliable, authoritative, informed, and relevant. The content of Neurodegenerative Diseases—Advances in Research and Treatment: 2013 Edition has been produced by the world’s leading scientists, engineers, analysts, research institutions, and companies. All of the content is from peer-reviewed sources, and all of it is written, assembled, and edited by the editors at ScholarlyEditions™ and available exclusively from us. You now have a source you can cite with authority, confidence, and credibility. More information is available at http://www.ScholarlyEditions.com/.

This book brings together the proceedings of Alzheimer's and Parkinson's Diseases: New Perspectives, the Sixth International Conference on Alzheimer's Disease and Parkinson's Disease, held recently in Seville, Spain, and discusses the latest developments in the basic science and therapy of Alzheimer's and Parkinson's diseases by leading specialists

"Providing a cross-section of current research, treatments and potential clinical developments, this volume of Advances in Pharmacology is an essential resource for biologists, pharmacologists and those engaged with Alzheimer's research."--P. [4] of cover.